The incidence of leukemia among young and middle-aged people is about 70%. At present, the treatment for young and middle-aged people with acute myeloid leukemia in remission has been using traditional methods such as chemotherapy or hematopoietic stem cell transplantation, with a cure rate of less than 40% with chemotherapy and about 70% with transplantation, but the prerequisite for such transplantation is to find a perfectly matched donor. Severe infections and related complications after transplantation are upwards of 70%.
Systematic microtransplantation trials and clinical studies on leukemia have been conducted and breakthroughs have been achieved. They have successively used microtransplantation in 101 middle-aged and young patients with acute myeloid leukemia in remission with unprecedented success, and through long-term observation and follow-up, confirmed that the 6-year disease-free survival rate and overall survival rate are 84.4% and 89.5%, respectively, and this result is better than the currently commonly used conventional chemotherapy and This result is much higher than the survival and cure rates of conventional chemotherapy and stem cell transplantation. The study was funded by the National Natural Science Foundation of China.
According to Hui-Sheng Ai, unlike traditional hematopoietic stem cell transplantation, “microtransplantation” has the advantages of strong anti-leukemic effect and fast hematopoietic recovery of traditional transplantation, but also cleverly avoids the problems of traditional transplantation such as “graft-versus-host disease”. The microtransplantation patients do not need such pre-treatment, but only input the activated healthy donor hematopoietic stem cells after chemotherapy, and after several courses of treatment, the donor cells are microchimerically implanted, which can continuously remove the residual leukemia cells in the body, and activate the patient’s own immune system to achieve the ultimate cure. The ultimate cure for leukemia. Microtransplantation is very safe and easy, with no transplantation-related complications, and is not restricted by the patient’s age or type, and can be tolerated by children as young as 80 years old or older.
Microtransplantation is a new and innovative technology based on non-cleared marrow transplantation, which is a “revolution” to traditional transplantation for the treatment of leukemia and provides a new safe and efficient means of cure and survival for more leukemia and tumor patients.